Neuroblastoma Market Research Report – Forecast to 2030

Global Neuroblastoma Market Research Report: Information by Diagnostics (MIBG Scan and Biopsy), by Treatment (Surgical), and by End User (Hospitals and Others)—Forecast till 2030

ID: MRFR/Pharma/5093-HCR | February 2023 | Region: Global | 90 Pages         

Neuroblastoma Market Speak to Analyst Request a Free Sample

Global Neuroblastoma Market

Neuroblastoma market is expected to grow steadily USD 470.81 Million by 2030, at CAGR 3.40% over the forecast period 2022-2030.

Segmentation
By Diagnostics MIBG Scan and Biopsy
By Treatment Surgical
By End User Hospitals and Others
Key Players
Companies Profiled   Corp.    APEIRON Biologics AG    LUMITOS AG    NANTGE Healthcare    Pfizer Inc.    GL Pharm Tech Corporation    Aetna Inc    RxStrategies    Inc.
Drivers
Market Driving Forces   increasing case of childhood cancer
Request a Free Sample

Neuroblastoma Market Overview


The Neuroblastoma Market is projected to reach USD 470.81 Million by 2030 at 3.40% CAGR during the forecast period 2022-2030. Neuroblastoma is a type of cancer that arises from immature nerve cells prevalent throughout the body. Children under the age of five are most commonly affected by the tumor. Backbone pain, weight loss, abdominal discomfort, enlarged stomach, bulging eyes, weight, crankiness, anemia, fever, bone pain, dark circles around the eyes, weakness, elevated blood pressure, and constipation or diarrhea are all indications of neuroblastoma. Neuroblastoma is divided into two types: high risk and low risk. Neuroblastoma with a high probability of recurrence has a poor prognosis and requires aggressive therapy.


The global market for Neuroblastoma is predicted to grow as the number of occurrences of the disease increases. The disease is caused by mutations in germline cells, changes in lifestyle, and a family history of neuroblastoma. Due to a well-developed healthcare sector and rising children's cancer incidences, the Americas are expected to lead the worldwide neuroblastoma market. In Europe, the increasing number of infants with cancer is mostly related to the enhanced healthcare system.


Segmentation


The neuroblastoma market has been segmented into diagnostics, treatment, and end user.


The market, on the basis of diagnostics, has been segmented into various tests, MIBG scan, imaging, and biopsy. The tests are further sub-segmented into bone marrow, tissue, urine, and blood.


The market, by treatment, has been segmented into surgery, chemotherapy, radiation therapy, stem cell transplant, immunotherapy, and monoclonal antibody treatment. The market, by end user, has been segmented into hospitals ambulatory surgical centers, diagnostic centers, research centers, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The neuroblastoma market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European neuroblastoma market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.


The neuroblastoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The neuroblastoma market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


United Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc., and others are some of the key players in the global neuroblastoma market.


Regional Market Summary


Global Neuroblastoma Market Share (%), by Region, 2017


Neuroblastoma Market Share


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports


Geographically, the Americas is predicted to dominate the global neuroblastoma market owing to a well-developed healthcare sector and growing incidences of childhood cancer. According to the American Society of Clinical Oncology (ASCO) in April 2018, article neuroblastoma accounts for 6% of all childhood cancers in the US. It was also indicated that it is the third most common type of cancer in infants. This influences the market growth in North America.


Europe is likely to hold the second largest position in the global neuroblastoma market. The market growth in this region is attributed to the increasing number of infant’s cancer with developed healthcare infrastructure.  According to the Cancer Research UK May 2016, statistics 1,821 new cases of children's cancer was listed in 2013-2015, in the UK. The increase in cases of childhood cancer in this region supports this market growth.


The neuroblastoma market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is predictable to be the fastest growing region due to the enormous patient population of childhood cancer and increasing development of hospitals for childhood cancer treatment in the Asia-Pacific region.


The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.


Global Neuroblastoma Market, by Diagnostics



  • Tests

  • Bone Marrow Testing

  • Tissue Testing

  • Urine and Blood Testing

  • MIBG Scan

  • Imaging

  • Biopsy


Global Neuroblastoma Market, by Treatment



  • Medications

  • Surgery

  • Chemotherapy

  • Radiation therapy

  • Stem Cell Transplant

  • Immunotherapy

  • Monoclonal antibody treatment


Global Neuroblastoma Market, by End User



  • Hospitals and clinics

  • Ambulatory Surgical Centers

  • Diagnostic Centers

  • Research centers

  • Others


Global Neuroblastoma Market, by Region


Americas



  • North America

  • US

  • Canada

  • South America


Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific


Middle East & Africa



  • Middle East

  • Africa


Global Neuroblastoma Market, by Key Players


United Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc., and others are some of the key players in the global neuroblastoma market.Recent Development


The United States Food and Drug Administration (FDA) Office has given Orphan Drug Designation to SACT-1, a repurposed small molecule drug for the treatment of patients with Neuroblastoma developed by Aptorum Group Limited, a clinical-stage biopharmaceutical company. Aptorum Group plans to submit an Investigational New Drug Application (IND) to start a phase 1b/2a clinical study for SACT-1 in neuroblastoma patients. SACT-1 is a repurposed small molecule medication that targets neuroblastoma and is used orally.


Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma, has acquired FDA approval for its Cyclophosphamide Injection in 500 mg/2.5 mL and 1 g/5 mL vials. Aurobindo's Cyclophosphamide Injection is used to treat malignant lymphomas, multiple myeloma, leukemias, Mycosis fungoides, Neuroblastoma, and more. The product will be released in the near future in the United States and will be made in Eugia's Indian factory.


Intended Audience



  • Manufacturers and vendors

  • Research associations related to  cancer in children

  • Hospitals and clinics

  • Various research and consulting firms



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 470.81 Million
  CAGR   3.40%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units    Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Diagnostics, Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   United Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions and new product developments
  Key Market Drivers   Rising prevalence of childhood cancer


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The neuroblastoma market is projected to grow at a 3.40% CAGR between 2022-2030.

The Americas is projected to command the largest share in the neuroblastoma market.

Key players profiled in the neuroblastoma market include RxStrategies, Inc., Aetna Inc, GL Pharm Tech Corporation, Pfizer Inc., NANTGE Healthcare, LUMITOS AG, APEIRON Biologics AG, and United Therapeutics Corp.

Rising prevalence of childhood cancer is boosting market growth.

High therapy cost and shortage of specialists may limit market growth.